D-2570 Shows High PASI Response Rates in Phase 2 Psoriasis Study
Key Takeaways
- In a phase 2 trial, once-daily D-2570 achieved PASI 75 responses in 85.0% to 90.0% of patients with moderate-to-severe plaque psoriasis at week 12 versus 12.5% with placebo.
- PASI 90, PASI 100, and sPGA 0/1 responses were also significantly higher across all 3 D-2570 dose groups compared with placebo.
- The study was limited by its small sample size and 12-week treatment period.
A novel oral TYK2 inhibitor produced significantly higher skin clearance rates than placebo in patients with moderate-to-severe plaque psoriasis, according to research published in Journal of the American Academy of Dermatology.
D-2570 is a TYK2 inhibitor under development for autoimmune diseases, including psoriasis and ulcerative colitis. In the double-blind trial, investigators randomized patients 1:1:1:1 to once-daily D-2570 at 18 mg, 27 mg, or 36 mg or placebo for 12 weeks. The primary endpoint was PASI 75 response at week 12.
D-2570 Achieves High PASI Response Rates at Week 12
At week 12, PASI 75 response rates ranged from 85.0% to 90.0% across the 3 D-2570 groups compared with 12.5% with placebo (P < .001 for all comparisons). PASI 90 responses ranged from 70.7% to 77.5% versus 5.0% with placebo (P < 0.001), while PASI 100 responses ranged from 39.0% to 50.0% versus 2.5% (P < 0.005). Static Physician Global Assessment scores of 0 or 1 were achieved by 80.5% to 87.5% of D-2570-treated patients compared with 20.0% receiving placebo (P < 0.001).
The investigators reported that D-2570 was well tolerated, with most treatment-emergent adverse events characterized as mild or moderate. Pharmacokinetic findings were described as favorable, and treatment suppressed IL-17A levels.
Small sample size and relatively short treatment and follow-up periods were cited as study limitations.
“D-2570 demonstrated a high efficacy with favorable safety profile in patients with moderate-to-severe plaque psoriasis,” the authors concluded.
Source
Zhang J, et al.Journal of the American Academy of Dermatology. 2025;94,143-150.